GlassScriptPhysician profile
Angela M Carson
NPI 1609240852
$1,333.88
in general payments reported to CMS, 2019-2025
21 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $809 · 2022: $74.19 · 2024: $61.98 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $228.94 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $212.16 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $162.14 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $132.25 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.37 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $92.26 | 2021-2025 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $91.02 | 2021-2025 | Uzedy |
| Vanda Pharmaceuticals INC. | $87.09 | 2021 | |
| Noven Therapeutics, LLC | $51.24 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.26 | 2024 | Qelbree |
| Axsome Therapeutics, INC. | $17.29 | 2025 | Auvelity |
| Corium, LLC | $15.36 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.99 | 2021 | |
| Lundbeck LLC | $14.96 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $14.60 | 2021 | |
| Alkermes, INC. | $13.84 | 2021 | |
| Tris Pharma INC | $13.76 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $12.82 | 2021 | |
| Adlon Therapeutics L.P. | $12.27 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.